Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

NCT02128269 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Screening discontinued early due to slow patient enrollment

Conditions

Antiphospholipid (aPL)-Positive

Interventions

BIOLOGICAL: Study Drug- ALXN1007

Sponsor

Alexion Pharmaceuticals, Inc.